Xbrane Biopharma AB Statistics

Total Valuation

Xbrane Biopharma AB has a market cap or net worth of SEK 276.53 million. The enterprise value is 416.30 million.

Market Cap	276.53M
Enterprise Value	416.30M

Important Dates

The next estimated earnings date is Friday, February 21, 2025.

Earnings Date	Feb 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Xbrane Biopharma AB has 1.53 billion shares outstanding. The number of shares has increased by 2,952.35% in one year.

Current Share Class	n/a
Shares Outstanding	1.53B
Shares Change (YoY)	+2,952.35%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	2.14%
Owned by Institutions (%)	7.56%
Float	1.49B

Valuation Ratios

PE Ratio	n/a
Forward PE	20.78
PS Ratio	0.77
PB Ratio	1.06
P/TBV Ratio	1.06
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.12
EV / Sales	2.08
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.35

Financial Position

The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.65.

Current Ratio	1.35
Quick Ratio	0.49
Debt / Equity	0.65
Debt / EBITDA	n/a
Debt / FCF	-0.55
Interest Coverage	-5.35

Financial Efficiency

Return on equity (ROE) is -103.07% and return on invested capital (ROIC) is -32.13%.

Return on Equity (ROE)	-103.07%
Return on Assets (ROA)	-18.63%
Return on Capital (ROIC)	-32.13%
Revenue Per Employee	3.07M
Profits Per Employee	-5.70M
Employee Count	93
Asset Turnover	0.23
Inventory Turnover	0.44

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -97.54% in the last 52 weeks. The beta is 1.09, so Xbrane Biopharma AB's price volatility has been similar to the market average.

Beta (5Y)	1.09
52-Week Price Change	-97.54%
50-Day Moving Average	0.20
200-Day Moving Average	0.32
Relative Strength Index (RSI)	43.55
Average Volume (20 Days)	10,303,737

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Xbrane Biopharma AB had revenue of SEK 199.81 million and -370.56 million in losses. Loss per share was -0.44.

Revenue	199.81M
Gross Profit	123.62M
Operating Income	-257.89M
Pretax Income	-304.77M
Net Income	-370.56M
EBITDA	-246.75M
EBIT	-257.89M
Loss Per Share	-0.44

Full Income Statement

Balance Sheet

The company has 30.59 million in cash and 170.36 million in debt, giving a net cash position of -139.77 million or -0.09 per share.

Cash & Cash Equivalents	30.59M
Total Debt	170.36M
Net Cash	-139.77M
Net Cash Per Share	-0.09
Equity (Book Value)	260.15M
Book Value Per Share	0.17
Working Capital	164.87M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -308.77 million and capital expenditures -677,000, giving a free cash flow of -309.44 million.

Operating Cash Flow	-308.77M
Capital Expenditures	-677,000
Free Cash Flow	-309.44M
FCF Per Share	-0.20

Full Cash Flow Statement

Margins

Gross margin is 61.87%, with operating and profit margins of -129.07% and -185.46%.

Gross Margin	61.87%
Operating Margin	-129.07%
Pretax Margin	-152.53%
Profit Margin	-185.46%
EBITDA Margin	-123.49%
EBIT Margin	-129.07%
FCF Margin	-154.87%

Dividends & Yields

Xbrane Biopharma AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2,952.35%
Shareholder Yield	-2,952.35%
Earnings Yield	-241.48%
FCF Yield	-111.90%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Xbrane Biopharma AB has an Altman Z-Score of -2.68. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.68
Piotroski F-Score	n/a